Floatz logo

Amitriptyline

Major Depressive Disorder

e-Therapeutics PLCSmall moleculePhase 4 / ApprovedDormant
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
89/ 100

Competitive context

198 Active assets in the Major Depressive Disorder cohort.

Asset / SponsorPhaseRating
Risperidone
Johns Hopkins University
Phase 4BBB
Selegiline
Corium Innovations, Inc.
Phase 4BBB
EDIVOXETINE
Eli Lilly and Company
Phase 3BBB
(1S,2R)-MILNACIPRAN
Allergan
Phase 4BBB
Brexpiprazole
Nova Scotia Health Authority
Phase 4BBB

View all 50 →

Same molecule, other indications

Amitriptyline is also rated in:

depressive disorderActive
BBB
Indicative · Phase 4
72 / 100
View asset →
headache disorderActive
BB
Indicative · Phase 4
70 / 100
View asset →
spinal cord injuryDormant
BB
Indicative · Phase 4
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →